Innate immune landscape in glioblastoma patient tumors

Glioblastoma is an extremely aggressive brain tumor with limited treatment options.

Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might be effective in this devastating malignancy.

Myeloid-derived innate immune cells, such as macrophages, microglia, and myeloid-derived suppressor cells, are known to be present within glioblastomas.

Previous work suggested that the tumor microenvironment triggers microglia and macrophages to polarize to a cell state that dampens immune responses to tumors; however, there has been only a limited assessment of the immune cell populations in patient tumors.

In this month’s issue of JCI Insight, Amy Heimberger and colleagues at the University of Texas MD Anderson Cancer Center provide a comprehensive analysis of myeloid lineage immune cells in the circulation and in tumors of glioblastoma patients.

Their extensive survey relied on immune phenotyping, whole genome microarray analysis, and microRNA expression profiling to characterize myeloid cells in surgical samples from 43 patients.

Their results surprisingly indicated that glioblastoma-associated myeloid cells were most similar to non-polarized cells.

Importantly, these findings suggest that strategies to stimulate myeloid cells to assume an anti-tumor identity may be possible and merit future exploration.

Contact our news editors

For any corrections of factual information, or to contact our editorial team, please see our contact page.

Please note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms of use.

Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.

Be the first to comment

Leave a Reply

Your email address will not be published.


*